Does the media refer more to CAMP or AVTX?

In the previous week, Avalo Therapeutics had 16 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 21 mentions for Avalo Therapeutics and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat Avalo Therapeutics' score of -0.16 indicating that CAMP4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CAMP4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CAMP or WVE?

In the previous week, WAVE Life Sciences had 7 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 12 mentions for WAVE Life Sciences and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat WAVE Life Sciences' score of 0.51 indicating that CAMP4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CAMP4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to CAMP or SANA?

In the previous week, Sana Biotechnology had 10 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 15 mentions for Sana Biotechnology and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat Sana Biotechnology's score of 0.67 indicating that CAMP4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CAMP4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CVAC or CAMP?

CAMP4 Therapeutics has a consensus target price of $8.36, suggesting a potential upside of 85.71%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CAMP4 Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CAMP4 Therapeutics 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.56

Is CVAC or CAMP more profitable?

CureVac has a net margin of 199.92% compared to CAMP4 Therapeutics' net margin of -2,193.72%. CureVac's return on equity of -23.03% beat CAMP4 Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% CAMP4 Therapeutics -2,193.72% -194.74% -95.64%

Is CAMP or GERN more profitable?

Geron has a net margin of -34.17% compared to CAMP4 Therapeutics' net margin of -2,193.72%. Geron's return on equity of -24.48% beat CAMP4 Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CAMP4 Therapeutics -2,193.72% -194.74% -95.64% Geron -34.17% -24.48% -10.30%

Does the media refer more to CAMP or GERN?

In the previous week, Geron had 9 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 14 mentions for Geron and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat Geron's score of 0.30 indicating that CAMP4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CAMP4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

CAMP4 Therapeutics (CAMP) Competitors

$4.50 -0.03 (-0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$4.49 -0.01 (-0.22%)

As of 04:39 PM Eastern

Compare

CAMP vs. AVTX, WVE, SANA, CVAC, and GERN

Should you buy CAMP4 Therapeutics stock or one of its competitors? CAMP4 Therapeutics's main competitors and comparable companies include Avalo Therapeutics (AVTX), WAVE Life Sciences (WVE), Sana Biotechnology (SANA), CureVac (CVAC), and Geron (GERN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CAMP4 Therapeutics compare to Avalo Therapeutics?

CAMP4 Therapeutics (NASDAQ:CAMP) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Avalo Therapeutics had 16 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 21 mentions for Avalo Therapeutics and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat Avalo Therapeutics' score of -0.16 indicating that CAMP4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CAMP4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

CAMP4 Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

CAMP4 Therapeutics currently has a consensus target price of $8.36, indicating a potential upside of 85.71%. Avalo Therapeutics has a consensus target price of $45.10, indicating a potential upside of 131.88%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Avalo Therapeutics has lower revenue, but higher earnings than CAMP4 Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	80.68	-$80.40M	-$2.36	N/A
Avalo Therapeutics	$60K	17,385.06	-$78.26M	-$4.37	N/A

Avalo Therapeutics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,193.72%. Avalo Therapeutics' return on equity of -58.03% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,193.72%	-194.74%	-95.64%
Avalo Therapeutics	N/A	-58.03%	-48.22%

87.1% of Avalo Therapeutics shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Avalo Therapeutics beats CAMP4 Therapeutics on 11 of the 15 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to WAVE Life Sciences?

CAMP4 Therapeutics (NASDAQ:CAMP) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

CAMP4 Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market.

CAMP4 Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	80.68	-$80.40M	-$2.36	N/A
WAVE Life Sciences	$42.73M	23.98	-$204.38M	-$1.09	N/A

In the previous week, WAVE Life Sciences had 7 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 12 mentions for WAVE Life Sciences and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat WAVE Life Sciences' score of 0.51 indicating that CAMP4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CAMP4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

89.7% of WAVE Life Sciences shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

WAVE Life Sciences has a net margin of -309.73% compared to CAMP4 Therapeutics' net margin of -2,193.72%. WAVE Life Sciences' return on equity of -50.36% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,193.72%	-194.74%	-95.64%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

CAMP4 Therapeutics currently has a consensus price target of $8.36, suggesting a potential upside of 85.71%. WAVE Life Sciences has a consensus price target of $22.53, suggesting a potential upside of 333.26%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Summary

WAVE Life Sciences beats CAMP4 Therapeutics on 12 of the 17 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Sana Biotechnology?

CAMP4 Therapeutics (NASDAQ:CAMP) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Sana Biotechnology had 10 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 15 mentions for Sana Biotechnology and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat Sana Biotechnology's score of 0.67 indicating that CAMP4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CAMP4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

CAMP4 Therapeutics currently has a consensus target price of $8.36, indicating a potential upside of 85.71%. Sana Biotechnology has a consensus target price of $9.50, indicating a potential upside of 158.86%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sana Biotechnology has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,193.72%. Sana Biotechnology's return on equity of -102.39% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,193.72%	-194.74%	-95.64%
Sana Biotechnology	N/A	-102.39%	-39.71%

CAMP4 Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

CAMP4 Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	80.68	-$80.40M	-$2.36	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

88.2% of Sana Biotechnology shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sana Biotechnology beats CAMP4 Therapeutics on 10 of the 14 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

CAMP4 Therapeutics has a consensus target price of $8.36, suggesting a potential upside of 85.71%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CAMP4 Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CAMP4 Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

CureVac has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
CAMP4 Therapeutics	$3.50M	80.68	-$80.40M	-$2.36	N/A

CureVac has a net margin of 199.92% compared to CAMP4 Therapeutics' net margin of -2,193.72%. CureVac's return on equity of -23.03% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
CAMP4 Therapeutics	-2,193.72%	-194.74%	-95.64%

In the previous week, CAMP4 Therapeutics had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for CAMP4 Therapeutics and 0 mentions for CureVac. CAMP4 Therapeutics' average media sentiment score of 1.25 beat CureVac's score of 0.00 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
CAMP4 Therapeutics	Positive

Summary

CureVac beats CAMP4 Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CAMP4 Therapeutics compare to Geron?

CAMP4 Therapeutics (NASDAQ:CAMP) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

CAMP4 Therapeutics has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	80.68	-$80.40M	-$2.36	N/A
Geron	$183.88M	5.35	-$83.50M	-$0.11	N/A

73.7% of Geron shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Geron has a net margin of -34.17% compared to CAMP4 Therapeutics' net margin of -2,193.72%. Geron's return on equity of -24.48% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,193.72%	-194.74%	-95.64%
Geron	-34.17%	-24.48%	-10.30%

CAMP4 Therapeutics presently has a consensus target price of $8.36, suggesting a potential upside of 85.71%. Geron has a consensus target price of $4.00, suggesting a potential upside of 161.44%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

CAMP4 Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, Geron had 9 more articles in the media than CAMP4 Therapeutics. MarketBeat recorded 14 mentions for Geron and 5 mentions for CAMP4 Therapeutics. CAMP4 Therapeutics' average media sentiment score of 1.25 beat Geron's score of 0.30 indicating that CAMP4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CAMP4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Geron beats CAMP4 Therapeutics on 9 of the 16 factors compared between the two stocks.

Get CAMP4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAMP vs. The Competition

Export

Metric	CAMP4 Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$284.27M	$3.75B	$7.09B	$12.99B
Dividend Yield	N/A	3.70%	2.57%	10.61%
P/E Ratio	-1.91	6.01	210.49	21.56
Price / Sales	80.68	1,286.98	598.82	90.87
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	4.41	18.08	13.24	6.24
Net Income	-$80.40M	-$13.23M	$3.45B	$347.70M
7 Day Performance	N/A	2.29%	2.03%	1.92%
1 Month Performance	N/A	0.79%	1.07%	1.05%
1 Year Performance	213.59%	53.96%	67.58%	19.53%

CAMP4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAMP CAMP4 Therapeutics	4.0264 of 5 stars	$4.50 -0.7%	$8.36 +85.7%	+225.9%	$284.27M	$3.50M	N/A	644	Positive News
AVTX Avalo Therapeutics	2.5029 of 5 stars	$19.68 +1.1%	$45.10 +129.2%	+108.9%	$1.05B	$60K	N/A	40	Earnings Report Analyst Upgrade Analyst Revision
WVE WAVE Life Sciences	3.2835 of 5 stars	$5.38 +6.4%	$22.53 +319.2%	-38.0%	$1.05B	$42.73M	N/A	240
SANA Sana Biotechnology	2.0291 of 5 stars	$3.77 -0.4%	$9.50 +151.7%	+21.2%	$1.05B	N/A	N/A	380	Earnings Report Analyst Revision
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAMP) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. AVTX, WVE, SANA, CVAC, and GERN

How does CAMP4 Therapeutics compare to Avalo Therapeutics?

Summary

How does CAMP4 Therapeutics compare to WAVE Life Sciences?

Summary

How does CAMP4 Therapeutics compare to Sana Biotechnology?

Summary

How does CAMP4 Therapeutics compare to CureVac?

Summary

How does CAMP4 Therapeutics compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CAMP4 Therapeutics (CAMP) Competitors

CAMP vs. AVTX, WVE, SANA, CVAC, and GERN

How does CAMP4 Therapeutics compare to Avalo Therapeutics?

Does the media refer more to CAMP or AVTX?

Which has more risk & volatility, CAMP or AVTX?

Do analysts recommend CAMP or AVTX?

Which has stronger earnings and valuation, CAMP or AVTX?

Is CAMP or AVTX more profitable?

Do institutionals and insiders believe in CAMP or AVTX?

Summary

How does CAMP4 Therapeutics compare to WAVE Life Sciences?

Which has more risk & volatility, CAMP or WVE?

Which has preferable valuation and earnings, CAMP or WVE?

Does the media prefer CAMP or WVE?

Do institutionals and insiders have more ownership in CAMP or WVE?

Is CAMP or WVE more profitable?

Do analysts recommend CAMP or WVE?

Summary

How does CAMP4 Therapeutics compare to Sana Biotechnology?

Does the media refer more to CAMP or SANA?

Do analysts rate CAMP or SANA?

Is CAMP or SANA more profitable?

Which has more risk & volatility, CAMP or SANA?

Which has stronger earnings & valuation, CAMP or SANA?

Do institutionals & insiders hold more shares of CAMP or SANA?

Summary

How does CAMP4 Therapeutics compare to CureVac?

Do analysts prefer CVAC or CAMP?

Do institutionals and insiders have more ownership in CVAC or CAMP?

Which has more risk & volatility, CVAC or CAMP?

Which has higher valuation and earnings, CVAC or CAMP?

Is CVAC or CAMP more profitable?

Does the media prefer CVAC or CAMP?

Summary

How does CAMP4 Therapeutics compare to Geron?

Which has higher earnings and valuation, CAMP or GERN?

Do insiders & institutionals hold more shares of CAMP or GERN?

Is CAMP or GERN more profitable?

Do analysts prefer CAMP or GERN?

Which has more risk and volatility, CAMP or GERN?

Does the media refer more to CAMP or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAMP vs. The Competition

CAMP4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools